Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug457 | BCG-Denmark Wiki | 0.45 |
| drug46 | 21% Ethanol plus essential oils Wiki | 0.32 |
| drug2293 | Matched Placebo Hydroxychloroquine Wiki | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3302 | Reference: Favipiravir 200 mg (Avigan) Wiki | 0.32 |
| drug355 | Ascorbic Acid and Zinc Gluconate Wiki | 0.32 |
| drug1488 | FITSTART+ PBI Wiki | 0.32 |
| drug478 | BLAfit® Wiki | 0.32 |
| drug1180 | Degarelix Wiki | 0.32 |
| drug365 | Assessment of cardiovascular diseases and cardiovascular risk factors Wiki | 0.32 |
| drug1630 | General Parenting Advice Wiki | 0.32 |
| drug1578 | Fremanezumab-Vfrm Wiki | 0.32 |
| drug4167 | Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures Wiki | 0.32 |
| drug6 | 0.12% Chlorhexidine Gluconate Wiki | 0.32 |
| drug788 | COVID19 vaccine Wiki | 0.32 |
| drug2459 | N-803 Wiki | 0.32 |
| drug5 | 0.075% Cetylpyridinium Chloride Wiki | 0.32 |
| drug22 | 1.5-2% w/v Hydrogen Peroxide Wiki | 0.32 |
| drug3957 | Test: Favipiravir 200 mg (LOQULAR) Wiki | 0.32 |
| drug1787 | Hydroxychloroquine - Daily dosing Wiki | 0.32 |
| drug4381 | attendance by ambulance crew Wiki | 0.32 |
| drug1617 | GX-19 Wiki | 0.32 |
| drug2849 | Peginterferon lambda alfa-1a subcutaneous injection Wiki | 0.32 |
| drug1523 | Fecal Microbiota Therapy (FMT) Wiki | 0.32 |
| drug4338 | Zinc Gluconate Wiki | 0.32 |
| drug20 | 1% w/v Povidone-iodide Wiki | 0.32 |
| drug1788 | Hydroxychloroquine - Weekly Dosing Wiki | 0.22 |
| drug354 | Ascorbic Acid Wiki | 0.16 |
| drug1047 | Convalescent Plasma Wiki | 0.06 |
| drug3728 | Standard of Care Wiki | 0.05 |
| drug2916 | Placebo Wiki | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000435 | Alcoholic Intoxication NIH | 0.32 |
| D000428 | Alcohol Drinking NIH | 0.26 |
| D003015 | Clostridium Infections NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008881 | Migraine Disorders NIH | 0.16 |
| D003428 | Cross Infection NIH | 0.16 |
| D000437 | Alcoholism NIH | 0.12 |
| D007239 | Infection NIH | 0.06 |
| D002318 | Cardiovascular Diseases NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D004630 | Emergencies NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002076 | Migraine HPO | 0.16 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.05 |
Navigate: Correlations HPO
There are 10 clinical trials
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.
Description: No evidence of SARS-CoV-2 infection at or before study day 28
Measure: Proportion of participants with no evidence of SARS-CoV-2 infection Time: Up to 28 daysDescription: Resolution of SARS-CoV-2 infection in the upper respiratory tract
Measure: Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples Time: Up to 14 daysThe overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration. This study will adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization.
Description: Disease progression defined as death or hospital admission or seeking emergency or urgent care within 15 days of randomization.
Measure: Number of patients with disease progression Time: 15 daysDescription: This scale was developed by a special World Health Organization (WHO) committee for quantifying COVID-19 illness severity. 8 = Death 7 = Hospitalized, intubated, mechanically ventilated and requiring additional organ support (pressors, renal replacement therapy) 6 = Hospitalized, intubated and mechanically ventilated 5 = Hospitalized on non-invasive ventilation or high flow nasal cannula 4 = Hospitalized on supplemental oxygen by mask or nasal prongs 3 = Hospitalized not on supplemental oxygen 2 = Not hospitalized with limitation in activity (continued symptoms) 1 = Not hospitalized without limitation in activity (no symptoms)
Measure: Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization Time: 30 daysDescription: Time to disease progression on the COVID Outpatient Ordinal Outcome Scale censored at 15 days after randomization. Scale provides more granular detail for outpatients than the WHO scale (adapted from Harrell and Lindsell, 2020). Worsening of symptoms is defined as any subject admitted to the hospital (level 1), seen in the emergency room (level 2), a patient who reports increased symptoms of 2 levels on the scale over a 24 hour period, or a patient who reports increased symptoms of 1 level observed for a 48 hour period. COVID Outpatient Ordinal Outcomes Scale 1 = patient requires care in the hospital 2 = patient requires care in the ED or urgent care 3 = patient at home with symptoms rated as moderate (defined as fever, shortness of breath, abdominal pain) 4 = patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness 5 = patient in their usual state of health
Measure: Time to disease progression Time: 15 daysBackground: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW). HCW are at high risk, currently HCW constitute 20% of all the COVID-19 cases in Denmark. Strategies to prevent absenteeism of HCW are urgently needed. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other infections; significant reductions in morbidity and mortality have been reported, and a plausible immunological mechanism has been identified. We hypothesize that BCG vaccination can reduce HCW absenteeism during the COVID-19 pandemic. Primary objective: To reduce absenteeism among HCW with direct patient contacts during the COVID-19 epidemic. Secondary objective: To reduce the number of HCW that are infected with SARS-CoV-2 during the COVID-19 epidemic and to reduce the number of hospital admissions amongst HCW with direct patient contacts during the COVID-19 epidemic. Study design: A multi-center randomized placebo controlled trial. Study population: 1500 HCW with direct patient contacts; defined as nurses, physicians and other medical staff working at emergency rooms and wards where COVID-infected patients are treated. Intervention: Participants will be randomized 1:1 to intradermal administration of a standard dose of BCG vaccine or placebo (saline). Main study parameters/endpoints: Primary endpoint: Number of days of (unplanned) absenteeism for any reason. Secondary endpoints: Number of days of (unplanned) absenteeism because of documented COVID infection. Cumulative incidence of hospital admissions. Risk for participants and impact: Based on previous experience and randomized controlled trials in adult and elderly individuals, the risks of BCG vaccination are considered low. The objective of this trial is to evaluate the potential beneficial effects of BCG vaccination through a lower work absenteeism rate of HCW and/or a mitigated clinical course of COVID infection.
This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.
Description: AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Measure: Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence Time: 2 weeksDescription: The 7-point ordinal scale is an assessment of the clinical status and is performed as the first assessment on each study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
Measure: Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale. Time: 2 weeksDescription: National Early Warning Score (NEWS) is based on 7 clinical parameters: respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, and level of consciousness.
Measure: Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS) Time: 2 weeksThe purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.
Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization. Time: 15 daysDescription: Determine if degarelix + BSC as compared to placebo + BSC reduces time to clinical improvement as defined by a decline of 2 categories or more from the baseline on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients or hospital discharge whichever comes first.
Measure: Time to clinical improvement Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces inpatient mortality.
Measure: Inpatient mortality Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of hospitalization.
Measure: Duration of hospitalization Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of intubation for mechanical ventilation.
Measure: Duration of intubation for mechanical ventilation. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the time to normalization of temperature (T < 37.5 for 48 hours)
Measure: Time to normalization of temperature. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the maximum severity of COVID-19 illness based on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients. Score range 1-7, higher scores equals worse outcome.
Measure: Maximum severity of COVID19 illness. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.
Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization. Time: 30 daysThe objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
Description: solicited local and systemic AEs after vaccination
Measure: Incidence of solicited adverse events Time: Through 1 year post vaccinationDescription: unsolicited AEs after vaccination
Measure: Incidence of unsolicited adverse events Time: Through 1 year post vaccinationDescription: percentage of subjects with SAEs
Measure: Incidence of serious adverse events Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination
Measure: Percentage of subjects who seroconverted after vaccination Time: Through 1 year post vaccinationDescription: NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination
Measure: Geometric mean titer (GMT) of neutralizing antibody level Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Antigen-specific IFN-γ T cell immune response assessed before/after vaccination
Measure: Change from baseline in antigen-specific IFN-g cellular immune response Time: Through 1 year post vaccinationThis is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.
Description: Incidence of Adverse Events 1 week post immunisation
Measure: Incidence of Adverse Events Time: 1 weeks post immunisationDescription: COVID19 neutralizing antibody titers post immunisation
Measure: COVID19 neutralizing antibody titers Time: 2 weeks post second immunisationDescription: Frequency of COVID19 spike specific T cells 3 weeks post second immunisation
Measure: COVID19 T cell immunogenicity Time: 3 weeks post second immunisationDescription: COVID19 spike specific antibody titers 6 months post second immunisation
Measure: Durability of antibody response Time: 6 months post immunisationBackground: The virus SARS-CoV-2 has spread rapidly throughout the world. Seniors are at high risk of severe COVID-19 when infected. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other infections; significant reductions in morbidity and mortality have been reported, and a plausible immunological mechanism has been identified: "trained innate immunity". The investigators hypothesize that BCG vaccination can reduce the risk of COVID-19 and other infections among senior citizens during the COVID-19 pandemic. Objectives: Primary objective: To reduce senior citizens' risk of acute infection during the COVID-19 pandemic. Secondary objectives: To reduce senior citizens' risk of SARS-CoV-2 infection during the COVID-19 pandemic. To reduce senior citizens' risk of self-reported respiratory illness during the COVID-19 pandemic. Study design: A placebo-controlled randomized trial. Study population: 1900 seniors 65 years of age or above. Intervention: Participants will be randomized 1:1 to intradermal administration of a standard dose of BCG vaccine or placebo (saline). Outcomes: Primary outcome: "Acute infection" identified either by a doctor, antibiotics use, hospitalization, or death due to infection. Secondary outcomes: Verified SARS-CoV-2 infection and self-reported respiratory illness. With an expected incidence of "acute infection" of 20%, the trial can show a 25% risk reduction in the the intervention group versus the placebo group by including a total of 1900 individuals, 950 individuals in each group. Risk for participants and impact: Based on previous experience and randomized controlled trials in adult and elderly individuals, the risks of BCG vaccination are considered low. If BCG can reduce the risk of acute infection in seniors by 25% it has tremendous public health importance, both during the COVID-19 pandemic and overall.
Description: Acute infection identified either by a doctor, antibiotics use, hospitalization or death due to infection.
Measure: Acute infection Time: 12 months after inclusionDescription: SARS-CoV-2 IgM/IgG antibodies
Measure: SARS-CoV-2 infection Time: 12 months after inclusionDescription: Self-reported respiratory illness is based on information on symptoms given by the participants in the biweekly questionnaire.
Measure: Self-reported respiratory illness Time: 12 months after inclusionTo understand the impacts of using a fixed orthotic facial exercise appliance (BLAfit®) for migraine reduction, as compared to medication (fremanezumab-vfrm) and control.
Description: The frequency and pain level of subjects' migraines will be assessed upon the conclusion of the study through surveying and comparing to previous survey data.
Measure: Frequency and Pain Level of Migraines Post-Treatment Time: 4 months after startRandomized, double-blind prospective trial to test the efficacy and acceptability of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 480 subject participants and one, 75-90 minute visit.
Description: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 15 Minutes Time: Baseline, 15 minutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 30 Minutes Time: Baseline, 30 MinutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 45 Minutes Time: Baseline, 45 MinutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 60 Minutes Time: Baseline, 60 MinutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports